Integrating Diverse Datasets Improves Developmental Enhancer Prediction by Erwin, GD et al.
Integrating Diverse Datasets Improves Developmental
Enhancer Prediction
Genevieve D. Erwin1,2, Nir Oksenberg2,3, Rebecca M. Truty1, Dennis Kostka4, Karl K. Murphy2,3,
Nadav Ahituv2,3, Katherine S. Pollard1,2,5*, John A. Capra6*
1Gladstone Institute of Cardiovascular Disease, San Francisco, California, United States of America, 2 Institute for Human Genetics, University of California San Francisco,
San Francisco, California, United States of America, 3Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco,
California, United States of America, 4Department of Developmental Biology and Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh,
Pennsylvania, United States of America, 5Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of
America, 6Center for Human Genetics Research and Department of Biomedical Informatics, Vanderbilt University, Nashville, Tennessee, United States of America
Abstract
Gene-regulatory enhancers have been identified using various approaches, including evolutionary conservation, regulatory
protein binding, chromatin modifications, and DNA sequence motifs. To integrate these different approaches, we
developed EnhancerFinder, a two-step method for distinguishing developmental enhancers from the genomic background
and then predicting their tissue specificity. EnhancerFinder uses a multiple kernel learning approach to integrate DNA
sequence motifs, evolutionary patterns, and diverse functional genomics datasets from a variety of cell types. In contrast
with prediction approaches that define enhancers based on histone marks or p300 sites from a single cell line, we trained
EnhancerFinder on hundreds of experimentally verified human developmental enhancers from the VISTA Enhancer Browser.
We comprehensively evaluated EnhancerFinder using cross validation and found that our integrative method improves the
identification of enhancers over approaches that consider a single type of data, such as sequence motifs, evolutionary
conservation, or the binding of enhancer-associated proteins. We find that VISTA enhancers active in embryonic heart are
easier to identify than enhancers active in several other embryonic tissues, likely due to their uniquely high GC content. We
applied EnhancerFinder to the entire human genome and predicted 84,301 developmental enhancers and their tissue
specificity. These predictions provide specific functional annotations for large amounts of human non-coding DNA, and are
significantly enriched near genes with annotated roles in their predicted tissues and lead SNPs from genome-wide
association studies. We demonstrate the utility of EnhancerFinder predictions through in vivo validation of novel embryonic
gene regulatory enhancers from three developmental transcription factor loci. Our genome-wide developmental enhancer
predictions are freely available as a UCSC Genome Browser track, which we hope will enable researchers to further
investigate questions in developmental biology.
Citation: Erwin GD, Oksenberg N, Truty RM, Kostka D, Murphy KK, et al. (2014) Integrating Diverse Datasets Improves Developmental Enhancer Prediction. PLoS
Comput Biol 10(6): e1003677. doi:10.1371/journal.pcbi.1003677
Editor: Uwe Ohler, Duke University, United States of America
Received August 15, 2013; Accepted May 6, 2014; Published June 26, 2014
Copyright:  2014 Erwin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This project was supported by NIH (http://www.nih.gov/) grants from NIGMS (GM082901, GM61390), NHGRI (HG005058, HG006768), NICHD
(HD059862), NIDDK (DK090382), NINDS (NS079231), and NHLBI (HL098179), a PhRMA Foundation fellowship (http://www.phrmafoundation.org/), a University of
California Achievement Awards for College Scientists (ARCS) Scholarship (https://www.arcsfoundation.org/), a gift from the San Simeon Fund (URL unavailable),
and institutional funds from the J. David Gladstone Institutes (http://gladstoneinstitutes.org/) as well as institutional funds from Vanderbilt University. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: kpollard@gladstone.ucsf.edu (KSP); tony.capra@vanderbilt.edu (JAC)
Introduction
Eukaryotic gene expression is regulated by a highly orchestrated
network of events, including the binding of regulatory proteins to
DNA, chemical modifications to DNA and nucleosomes, recruit-
ment of the transcriptional machinery, splicing, and post-
transcriptional modifications. Enhancers are genomic regions that
influence the timing, amplitude, and tissue specificity of gene
expression through the binding of transcription factors and co-
factors that increase transcription (as reviewed in [1,2]). In
humans, genetic variation in enhancer regions is implicated in a
wide variety of developmental disorders, diseases, and adverse
responses to treatments [3,4,5].
Enhancers have been discovered in introns, exons, intergenic
regions megabases away from their target genes [6], and even on
different chromosomes [7]. An enhancer frequently drives only
one of many domains of a gene’s expression [8,9] and different cell
types accordingly exhibit considerable differences in their active
enhancers [10,11]. This modularity enables the creation of
complex regulatory programs that can evolve relatively easily
between closely related species [12,13].
Individual enhancers were initially identified using transgenic
assays in cultured cell lines [14,15] and later in vivo in model
organisms, such as mouse, Drosophila, and zebrafish. In the in vivo
experiments, a construct containing the sequence to be tested for
enhancer activity, a minimal promoter, and a reporter gene (e.g.,
lacZ) is injected into fertilized eggs, and transgenic individuals are
assayed for reporter gene expression.
Early efforts to find enhancers at the genome scale used
comparative genomics. Several studies assayed non-coding regions
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conserved across diverse species for enhancer activity [16,17,18],
since functional non-coding regions likely evolve under negative
selection. This approach identified many enhancers at a range of
levels of evolutionary conservation [19,20,21]. However, relying
on evolutionary conservation alone has several shortcomings:
many characterized enhancers are not conserved between species
[22], non-coding conservation is not specific to enhancer elements,
and evolutionary patterns provide little information about the
tissue and timing of enhancer activity.
Enhancer prediction has been revolutionized by recent techno-
logical advances, including chromatin immunoprecipitation cou-
pled with high-throughput sequencing (ChIP-seq) [23], RNA
sequencing (RNA-seq), and sequencing of DNaseI-digested
chromatin (DNase-seq) [24] or formaldehyde-assisted isolation of
regulatory elements (FAIRE-seq) [25]. These ‘‘functional geno-
mics’’ assays enable genome-wide measurement of histone
modifications, binding sites of regulatory proteins, transcription
levels, and the structural conformation of DNA. The ENCODE
project [26], FANTOM project [27], and similar studies focused
on specific cell types [28,29] have dramatically increased the
amount of publicly available functional genomics data.
Functional genomics studies revealed several genomic signatures
of active enhancers. For example, known enhancers are associated
with the unstable histone variants H3.3 and H2A.Z [30,31] and
low nucleosome occupancy [32], although these chromatin states
are not unique to enhancers. Monomethylation of lysine 4 on
histone H3 (H3K4me1), a lack of trimethylation at the same site
(H3K4me3), and acetylation of lysine 27 on histone H3
(H3K27ac) may distinguish active enhancers from promoters
[10,33,34], enhancers that are ‘‘poised’’ for activity later in
development [35,36], and regulatory elements that repress gene
expression [37,38]. Additional features that pinpoint specific
classes of active enhancers include binding of the transcriptional
cofactor p300/CBP [18,39,40,41], clusters of transcription factor
(TF) binding sites [42,43,44,45], and enhancer RNA transcription
(eRNAs) [46]. Collectively, functional genomics data have
pinpointed the locations of many novel enhancers and yielded
insights into sequence and structural determinants of enhancer
activity. However, these patterns have not proven to be universal
[47,48], and there is unlikely to be a single chromatin signature
that identifies all classes of enhancers [11,49,50].
Given the complexity of these functional genomics data sets,
computational methods have been developed to improve and
generalize the enhancer predictions made from simple combina-
tions of these data. Support vector machines (SVMs) and linear
regression models trained to interpret DNA sequence motifs
underlying known enhancers have successfully identified novel
enhancers active in heart [51], hindbrain [52], and muscle [53]
development. Another approach used SVMs to learn patterns of
short DNA sequence motifs that distinguish markers of potential
enhancers, such as p300 and H3K4me1, in different cellular
contexts [54,55]. Random forests have been used to predict p300
binding sites from histone modifications in human embryonic stem
cells and lung fibroblasts [56]. Machine-learning algorithms have
also been applied to the related problem of selecting functional TF
binding sites out of the thousands of hits to a TF’s binding motif
throughout the genome [57,58,59,60,61,62,63]. Finally, two
groups have taken a less supervised approach and used hidden
Markov models (ChromHMM) [64] and dynamic Bayesian
networks (Segway) [65] to segment the human genome into
regions with unique signatures in ENCODE data and then
assigned potential functions, such as enhancer activity, to these
states.
While rich datasets coupled with sophisticated algorithms have
successfully identified many novel enhancers, comprehensive
enhancer prediction is challenging for two main reasons. First,
no single type of data is currently sufficient to identify all
enhancers active in a given context. Many of the approaches
described above use a single mark or motif as a proxy for an
enhancer, but this gives an incomplete representation of all
biologically active enhancers. Second, while a great deal of
functional genomics data are available for different cell lines and
tissues, it is not understood how informative experiments in a given
cellular context are indicative of enhancer activity in other
contexts.
With these issues in mind, we introduce EnhancerFinder, a new
two-step machine-learning method for predicting enhancers and
their tissue specificity. In machine learning, a classification
algorithm is trained to distinguish between labeled training
examples (e.g., enhancers and non-enhancers) based on features
of these labeled examples (e.g., evolutionary conservation,
chromatin signature, DNA sequence). The trained classifier can
then be used to predict the labels for uncharacterized genomic
regions (e.g., which ones are enhancers). Our approach employs
two rounds of a supervised machine-learning technique called
multiple kernel learning (MKL) [66,67]. MKL is based on the
theory of SVMs [68], but provides greater flexibility to combine
diverse data (e.g., evolutionary conservation, sequence motifs, and
functional genomics data from different cellular contexts) and to
interpret their relative contributions to the resulting predictions.
Our implementation of EnhancerFinder applies MKL in two steps
with the goal of generating a genome-wide set of developmental
enhancers to better characterize gene regulation during develop-
ment. The algorithm, which is trained using in vivo validated
enhancers from the VISTA enhancer database [69] and publicly
available genomic data, first aims to distinguish human develop-
mental enhancers from the genomic background and then in a
second step predicts enhancer tissue specificity. In contrast to most
other enhancer prediction strategies, which are trained on
epigenetic marks or sequence motifs that serve as a proxy for a
subset of all active enhancers, our use of a heterogeneous and in
vivo validated set of enhancers, enables us to investigate the
Author Summary
The human genome contains an immense amount of non-
protein-coding DNA with unknown function. Some of this
DNA regulates when, where, and at what levels genes are
active during development. Enhancers, one type of
regulatory element, are short stretches of DNA that can
act as ‘‘switches’’ to turn a gene on or off at specific times
in specific cells or tissues. Understanding where in the
genome enhancers are located can provide insight into
the genetic basis of development and disease. Enhancers
are hard to identify, but clues about their locations are
found in different types of data including DNA sequence,
evolutionary history, and where proteins bind to DNA.
Here, we introduce a new tool, called EnhancerFinder,
which combines these data to predict the location and
activity of enhancers during embryonic development. We
trained EnhancerFinder on a large set of functionally
validated human enhancers, and it proved to be very
accurate. We used EnhancerFinder to predict tens of
thousands of enhancers in the human genome and
validated several of the predictions near three important
developmental genes in mouse or zebrafish. EnhancerFin-
der’s predictions will be useful in understanding functional
regions hidden in the vast amounts of human non-coding
DNA.
Integrative Developmental Enhancer Prediction
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complex suite of features that underlie active regulatory regions.
With appropriate training data, EnhancerFinder could be applied
to study gene regulation at other developmental stages.
Our analyses demonstrate that EnhancerFinder’s integration of
diverse types of data from different cellular contexts significantly
improves prediction of validated enhancers over approaches based
on a single context or type of data. We find that enhancers active
in some developmental contexts are easier to identify than others.
Applying EnhancerFinder to the entire human genome allowed us
to predict more than 80,000 developmental enhancers, with tissue-
specific predictions for brain, limb, and heart. These predictions
significantly overlap known non-coding regulatory regions and are
enriched near relevant genome-wide association study (GWAS)
lead single nucleotide polymorphisms (SNPs) and genes expressed
in the predicted tissue. To illustrate the utility and accuracy of our
genome-wide enhancer predictions, we used them to investigate
the enhancer landscape near three developmentally expressed
genes. First, we screened predicted enhancers near FOXC1 and
FOXC2 in transgenic zebrafish, and found that 70% (7 of 10) of
tested EnhancerFinder predictions have confirmed (6) or sugges-
tive (1) developmental enhancer activity. In addition, we validated
a novel cranial nerve enhancer near the ZEB2 locus using a
transgenic mouse enhancer assay. Taken together, our results
suggest that the EnhancerFinder approach of integrating diverse
data sets significantly improves prediction of biologically active
enhancers, providing high-confidence candidate enhancers for
studies in developmental gene regulation.
Results
We present EnhancerFinder, a machine learning-based en-
hancer prediction pipeline that allows the seamless integration of
feature data from a variety of experimental techniques and
biological contexts that have previously been used individually to
predict enhancers (Figure 1). We use MKL to integrate these data.
MKL algorithms learn a weighted combination of different
‘‘kernel’’ functions that quantify the similarity of different feature
data in order to make predictions. In EnhancerFinder, we use
three kernels based on different types of biological feature data:
DNA sequence motifs, evolutionary conservation patterns, and
functional genomics datasets.
EnhancerFinder could be used to predict enhancers active at
any stage and tissue. In this study, we evaluate EnhancerFinder’s
ability to predict developmental enhancers and their tissue
specificity.
A two-step approach to tissue-specific enhancer
prediction
Step 1 of our pipeline aims to distinguish all enhancers active in
the context of interest (e.g., a specific developmental stage) from
non-enhancer regions. Step 2 then builds classifiers to predict the
tissues in which the enhancer candidates from Step 1 are active.
This two-step approach allows us to accurately identify enhancers,
while also distinguishing their tissues of activity.
We train and evaluate EnhancerFinder using the VISTA
Enhancer Browser, which at the time of our analysis contained
over 700 human sequences with experimentally validated
enhancer activity in at least one tissue at embryonic day 11.5
(E11.5) in transgenic mouse embryos. VISTA also contained a
similar number of regions without enhancer activity in this
context. E11.5 in mouse development roughly corresponds to E41
(Carnegie stage 17 [70]) in human development. In Step 1 of
EnhancerFinder, we used all 711 VISTA enhancers as positive
training data, and for negative training data, we created a set of
711 random regions matched to the length and chromosome
distribution of the positives to represent the genomic background.
We did not use the VISTA negatives as negative training examples
in Step 1, because they are not representative of all non-enhancer
regions (see below). Our goal in Step 1 is to develop a method that
can be used to scan the whole genome and distinguish
developmental enhancer regions from non-enhancer regions.
The second step of EnhancerFinder aims to distinguish
enhancers active in a given embryonic tissue from non-enhancers
and enhancers active in other tissues. We consider all enhancers in
VISTA with activity in a tissue of interest as positives and all other
regions in VISTA (including regions not active at E11.5) as
negatives (see Methods). This second step that includes enhancers
active in other tissues as negatives in the training proves to be
essential for obtaining high specificity in predicting tissue of
activity (see below), and it is important to do this in two steps
rather attempting to distinguish enhancers of a given tissue from
genomic background in one step.
To evaluate EnhancerFinder, we compared it to several
commonly used enhancer prediction approaches. Unless otherwise
noted, we evaluated the performance of all prediction algorithms
using 10-fold cross validation to compute the area under the curve
(AUC) for receiver operating characteristic (ROC) curves. We also
computed precision-recall curves (Figure S1) and compared power
at a low false positive rate.
Building a general predictor from a biased training set
Because EnhancerFinder learns enhancer signatures from a
training data set, we first explored biases in the VISTA enhancers
that might affect how well EnhancerFinder could generalize to the
whole genome. The genomic regions tested by VISTA were not
selected randomly, and thus their positives do not represent a
random sample of active enhancers. Nearly all regions tested by
VISTA are evolutionarily conserved across mammals (706 of 711
positives and 727 of 736 negatives). Since our goal is to predict a
broadly applicable, high confidence set of developmental enhanc-
ers, we did not include this feature when making genome wide
predictions. However, with this bias in mind, we did evaluate
several models that incorporate the degree of evolutionary
conservation (see below).
In addition to conservation, several studies deposited in VISTA
have considered enhancer-associated proteins and histone marks,
such as p300, H3K27ac, and H3K4me1. We collected all data sets
of these types from ENCODE and computed their overlap with
VISTA enhancers. Fewer than half of the VISTA positives are
marked by all three of p300, H3K27ac, and H3K4me1 (from any
data set), with substantial percentages marked by only one or two
and 13% (93/711) marked by none (Figure S2). These findings
indicate that VISTA positives are not highly biased towards a
single type of ChIP-seq feature, motivating us to include these
features in our genome-wide predictions, with the caveat that the
trends we observe for VISTA positives might not generalize to all
classes of enhancers. Our analysis also suggests that the standard
practice of equating active enhancers with all regions marked by a
single ChIP-seq feature, or even the union of overlapping peaks
from several ChIP-seq experiments, will fail to identify all active
enhancers in a given context.
EnhancerFinder integrates diverse data types to
accurately identify developmental enhancers
EnhancerFinder predicts enhancers by integrating classifiers
based on distinct data types. In our first evaluation of
EnhancerFinder, we consider: functional genomics data, evolu-
tionary conservation patterns, and DNA sequence motifs. Com-
Integrative Developmental Enhancer Prediction
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bining these different approaches enables EnhancerFinder to
accurately distinguish enhancers from the genomic background
(Figure 2A; AUC=0.96).
The functional genomics component of EnhancerFinder (which
we refer to as All Functional Genomics) is a linear SVM that
incorporates 2469 datasets generated by the ENCODE project
and smaller scale studies. These include DNaseI hypersensitivity
data and ChIP-Seq for p300, many histone modifications, and
many TFs from many adult and embryonic tissues and cell lines
(Table S1). DNA sequence patterns are integrated via a 4-
spectrum kernel (DNA Motifs), which summarizes the occur-
rence of all length four DNA sequences (4-mers) in input regions
[71]. We found that little was gained by increasing k, considering
multiple k simultaneously, or incorporating knowledge of tran-
scription factor binding site (TFBS) motifs as in a previous
approach [52] (Figures S3 and S4). Finally, evolutionary
conservation information is incorporated with a linear SVM that
uses mammalian phastCons scores [72] as features (Evolutionary
Conservation).
EnhancerFinder performs significantly better than
enhancer prediction approaches based on a single type
of data
One motivation for developing EnhancerFinder was to explore
whether combining previous successful approaches to enhancer
prediction would improve performance. Each of the classifiers
combined in EnhancerFinder is representative of a different
strategy for predicting enhancers. Thus, we compared the
performance of EnhancerFinder to each of its constituents, which
are SVMs trained on the same enhancer data as EnhancerFinder,
but using only one type of the data features (e.g., only sequence
motifs). EnhancerFinder significantly outperformed each of the
individual classifiers (Figure 2A; p= 2.0E-7 for Evolutionary
Conservation, p = 2.6E-8 for DNA Motifs, and p= 4.4E-16 for
All Functional Genomics, McNemar’s test), suggesting that
these different types of data capture unique aspects of enhancers
that are not completely encompassed by any single data type.
Not surprisingly, we found that of the three component
classifiers in EnhancerFinder, Evolutionary Conservation
yields the best performance (AUC=0.93). As noted above, nearly
all regions tested for enhancer activity by VISTA (positives and
negatives) are evolutionarily conserved compared to the genomic
background. Nonetheless, considering additional features signifi-
cantly improved predictions. The DNA Motifs (AUC=0.88) and
All Functional Genomics (AUC=0.89) classifiers also exhibit
strong performance, but also do not perform as well as the
combined classifier. EnhancerFinder has nearly twice the power of
any of the individual classifiers at a 5% false positive rate (FPR),
and its power advantage is even larger at lower FPRs.
All Functional Genomics, DNA Motifs, and Evolution-
ary Conservation achieve roughly similar performance from
different feature data, but each individual classifier predicts a
somewhat different set of enhancers during evaluation (Figure 2B).
Roughly two-thirds of the enhancer predictions are shared
between the three classifiers. The improvement provided by
combining these data argues that these data sources are indeed
complementary.
We also compared EnhancerFinder’s performance with several
current computational methods used to identify enhancers. We
were able to make the most direct comparison with CLARE, a
popular method for identifying enhancers from DNA sequence
data, i.e., transcription factor binding site motifs and other
sequence patterns [73]. This approach, which has been success-
fully applied in several contexts [51,52,53,74], makes few
assumptions about the input, and is publicly available as a web
server. On our Step 1 enhancer prediction task, we find that
CLARE achieves an ROC AUC of 0.79. This is much lower than
DNA Motifs (AUC=0.88), our approach based on sequence
data alone, and the full EnhancerFinder (AUC=0.96;
Figure 2C). At a 5% FPR, the power of CLARE is about 20%,
compared to approximately 30% for DNAMotifs and more than
60% for EnhancerFinder.
Comparisons with additional methods were complicated by the
fact that most were developed in different contexts. We designed
EnhancerFinder specifically to predict biologically active develop-
mental enhancers. Most existing approaches focus on data from a
single cell line and define enhancers based on specific enhancer-
associated marks or proteins (such as p300 in human embryonic
stem cells) rather than biological activity. Thus, we did not
anticipate that they would perform as well as EnhancerFinder at
developmental enhancer prediction. However, since the predic-
tions of these methods are commonly used outside the specific
contexts in which they were made, we believe that it is useful to
evaluate how well they can identify developmental enhancers and
how much the EnhancerFinder approach applied to developmen-
tal enhancers improves on their performance.
In particular, we compared EnhancerFinder to ChromHMM
and Segway [64,65], two unsupervised machine learning methods
for segmenting the genome into a small number of functional
‘‘states’’ based on consistent patterns in ENCODE data for
individual cell lines. The states resulting from the segmentations of
each cell line’s data are annotated by hand into predicted
functional classes, which include enhancer activity. To evaluate
these methods, we considered the states overlapping our training
and testing regions. Any region with an overlapping enhancer state
was considered a predicted enhancer and all others were predicted
non-enhancers. In this way, we obtained a single point in ROC
space for the state predictions. Since there is no score or
confidence value associated with the state assignments, a full
ROC curve could not be created for these methods. Figure 2C
gives the performance for several versions of ChromHMM and
Segway based on ENCODE data from different cell lines. Both
methods perform better than random, but considerably worse than
EnhancerFinder and CLARE (p<0). We stress that, in contrast to
our supervised method, these methods were not explicitly trained
to perform the same task as EnhancerFinder, and thus we did not
expect them to perform as well as EnhancerFinder. Indeed, these
results argue that their utility in identifying developmental
enhancers is limited compared to specialized approaches.
Figure 1. Overview of the EnhancerFinder enhancer prediction pipeline. In our two-step approach, regions of the genome are characterized
by diverse features, such as their evolutionary conservation, regulatory protein binding, chromatin modifications, and DNA sequence patterns. For
each step, appropriate positive (green) and negative (purple) training examples are provided as input to a multiple kernel learning (MKL) algorithm
that produces a trained classifier. We used 10-fold cross validation to evaluate the performance of all classifiers. In Step 1, we trained a classifier to
distinguish between known developmental enhancers from VISTA and the genomic background. In Step 2, we trained several classifiers to
distinguish enhancers active in tissues of interest from those without activity in the tissue according to VISTA. We applied the trained enhancer
classifier from Step 1 to the entire human genome to produce more than 80,000 developmental enhancer predictions. We then applied the tissue-
specific enhancer classifiers from Step 2 to further refine our predictions.
doi:10.1371/journal.pcbi.1003677.g001
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Integrating diverse functional genomics data improves
enhancer prediction
As illustrated above, our machine learning prediction and
evaluation framework enabled us to quantitatively explore the
utility of different genomics datasets in enhancer prediction by
creating classifiers based on different types of data (i.e., sequence
motifs, evolutionary conservation, and functional genomics) and
comparing their performance. We also used this framework to
investigate other questions about the utility of different subsets of
these data for enhancer prediction. For example, one might expect
that some of the datasets included in All Functional Genomics
(e.g., experiments in cancer cell lines or adult tissues) would not be
as useful as others (e.g., experiments in embryonic tissues) for
predicting developmental enhancers, and that limiting the features
examined by the classifier to the most relevant experiments might
improve performance.
To explore this hypothesis, we trained linear SVM classifiers to
predict VISTA enhancers (as in Step 1 of EnhancerFinder) based
on different subsets of all the functional genomics features (Table 1)
and compared their performance. First, we considered a collection
of 244 datasets from embryonic tissues and cell lines (Embryonic
Functional Genomics). Next, we created a classifier that
considers data from a wider range of contexts by training a linear
SVM using a large, manually curated set of 509 potentially
relevant functional genomics data sets (Relevant Functional
Genomics). This set includes embryonic datasets, along with
additional DNaseI and ChIP-seq data from adult tissues and cell
lines related to the dominant tissues of activity in VISTA. For
example, we included data from human cardiac myocytes, since
there are many developmental heart enhancers in our training
examples. We compared these to the All Functional Genomics
classifier described above that uses all 2496 functional genomics
features.
All Functional Genomics (AUC=0.89) performed slightly,
but not significantly, better than Relevant Functional Geno-
mics (AUC=0.87; p= 0.16), and both significantly outperformed
Embryonic Functional Genomics (AUC=0.83; p = 9.2E-9
and p=2.7E-6, respectively) (Figure 3A). At low FPRs, the
differences in power between these classifiers were modest. The
Embryonic Functional Genomics classifier included the most
time-appropriate datasets, yet its performance was improved by
Figure 2. Combining diverse data using EnhancerFinder
improves the identification of developmental enhancers. (A)
Enhancer prediction strategies based on functional genomics data,
evolutionary conservation, and DNA sequence motif patterns all
perform well, but EnhancerFinder, which combines these data, provides
significant improvement over each of them alone (p,2.0E-7 for all). (B)
Each of the approaches from (A) predicts that somewhat different sets
of the VISTA regions are enhancers. This suggests that complementary
information is contained in each data source. EnhancerFinder (not
shown), which combines them, captures many of the enhancers that
are unique to each source; it predicts 25 of the 44 enhancers unique to
Functional Genomics, 30 of the 76 unique to DNA Sequence
Motifs, and 34 of the 111 unique to Evolutionary Conservation. (C)
EnhancerFinder outperforms CLARE, a successful enhancer prediction
method based on known regulatory motifs. We also evaluated the
enhancer states predicted by ChromHMM and Segway, two unsuper-
vised clustering methods that have been used to segment the genome
into different functional states based on patterns in functional
genomics data, though these methods were not applied to develop-
mental contexts. The different X’s represent state predictions based on
data from different ENCODE cell types: GM12878 (blue), H1-hESC
(violet), HepG2 (brown), HMEC (tan), HSMM (gray), HUVEC (light green),
K562 (green), NHEK (orange), NHLF (light blue), and all contexts
combined (red).
doi:10.1371/journal.pcbi.1003677.g002
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including additional data sets that seem less relevant to our
classification problem a priori. Thus, we conclude that it can be
advantageous to consider a range of functional genomics features,
especially when few features are available from the context of
interest. The utility of these additional data sets might indicate that
some enhancer features are stable across cell types and develop-
mental stages, but it could also reflect information these data
provide about genomic regions that are not active enhancers
during development (see Discussion).
Histone marks and p300 provide complementary
information about enhancer activity
We also explored the utility of individual functional genomics
datasets that are often used as proxies for developmental
enhancers by creating three linear SVM classifiers: H3K27ac,
H3K4me1, and p300. These SVMs were trained to distinguish
VISTA positives from the genomic background (Step 1) using all
available data of the specified type from ENCODE, which include
a range of cell types and tissues (Table S1). All three classifiers
performed better than random (Figure 3B). H3K4me1
(AUC=0.72) and p300 (AUC=0.68) performed similarly
(p = 0.25), with p300 performing best at low FPRs and
H3K4me1 best at higher FPRs. Both significantly outperformed
H3K27ac (AUC=0.61; p = 9.4E-15 and p= 5.5E-9, respective-
ly); however, we caution against extrapolating from this compar-
ison, since it may reflect biases in the feature sets available and the
VISTA positives. Since combinations of these features are often
used to predict enhancers, we next trained a linear SVM classifier
(Basic Functional Genomics) that includes all three data types
together. The combined classifier significantly outperforms all the
individual classifiers (AUC=0.77; p,2E-7 for each), suggesting
that each data type contributes unique information about
enhancer activity. Also, all four SVM classifiers achieved much
better performance than the common approach of simply
considering regions overlapping with these data (Figure S5).
EnhancerFinder also learns weights for individual features
within classifiers that reflect their contribution to the enhancer
predictions. We found that features known to be associated with
enhancer activity in relevant cellular contexts generally receive
positive weights, while those associated with other types of
elements received negative weights (Text S1 and Figure S6).
EnhancerFinder’s two-step approach enables tissue-
specific enhancer prediction
In the previous sections, we focused on generic developmental
enhancer prediction (Step 1 of EnhancerFinder). Step 2 of
EnhancerFinder applies a second round of MKL to refine and
further annotate predicted enhancers from Step 1 (Figure 1). In
this study, Step 2 consists of training an MKL classifier to
distinguish VISTA enhancers active in a given tissue from VISTA
regions without activity in that tissue, i.e., non-enhancers from
VISTA plus enhancers for other tissues. We did not require that
the positive training examples be active only in the tissue of interest.
Using the same feature data as in Step 1, we created tissue-specific
classifiers for all tissues with more than 50 examples in VISTA:
forebrain, midbrain, hindbrain, heart, limb, and neural tube.
The performance of EnhancerFinder’s tissue specificity predic-
tions varied dramatically between tissues (Figure 4), with the best
performance for heart (AUC=0.85), followed by limb
(AUC=0.74), forebrain (AUC=0.72), midbrain (AUC=0.72),
hindbrain (AUC=0.69), and neural tube (AUC=0.62), which was
the worst of the tested tissue classifiers, but better than random.
We combined all brain enhancers into one class, and the
performance of this generic brain classifier was similar to that of
the more specific brain classifiers (AUC=0.73). The Enhancer-
Finder tissue-specific classifiers trained with all data types
performed well for most tissues (Table 1); however, classifiers
based on functional genomics alone often performed as well as the
full EnhancerFinder classifier, suggesting functional genomics data
are more informative about developmental enhancer tissue
specificity than degree of conservation or sequence motifs.
Most previous efforts to predict tissue-specific enhancers have
performed a single training step using enhancers or enhancer
marks present in the tissue of interest as positives and non-
enhancer regions or the genomic background as negatives. To test
whether our two-step method improves upon these previous
approaches, we trained one-step MKL tissue-specific classifiers
and compared their predicted tissue distributions to those of
validated enhancers from the VISTA database (Figure 5A). First,
we trained a set of tissue-specific classifiers using enhancers active
in each tissue as positives and the genomic background as
negatives. These classifiers predict very similar sets of enhancers
regardless of the target tissue; and they vastly overestimate the
number of enhancers that are active in multiple tissues (95% of
predictions versus 8% of VISTA) and the number of true
enhancers of each tissue (Figure 5B). In contrast, classifiers trained
as in Step 2 of EnhancerFinder, i.e., using tissue-specific enhancers
as positives and a mix of enhancers active in other tissues and
regions with no activity in VISTA as negatives, show much greater
tissue-specificity in their predictions (76%) and a similar amount of
overlap as among known enhancers (Figure 5C).
Heart enhancers are easier to identify due to several
unique attributes
The relative ease of identifying heart enhancers is likely due to
several unique characteristics. Known heart enhancers at E11.5
are more evolutionarily conserved than genomic background, but
significantly less conserved than enhancers in other tissues [39,41].
In addition, we observed that heart enhancers at this develop-
mental stage are uniquely close to the nearest transcription start
site (TSS) (Figure S7). These two patterns are consistent with a
Table 1. Performance (ROC AUC) of classifiers on each tissue-specific enhancer prediction task (Step 2).
Heart Limb Forebrain Midbrain Hindbrain Neural Tube
Evolutionary Conservation 0.78 0.58 0.52 0.54 0.53 0.52
DNA Motifs 0.83 0.64 0.66 0.63 0.62 0.60
Functional Genomics 0.86 0.74 0.72 0.72 0.69 0.62
Enhancer Finder 0.85 0.74 0.72 0.72 0.69 0.62
doi:10.1371/journal.pcbi.1003677.t001
Integrative Developmental Enhancer Prediction
PLOS Computational Biology | www.ploscompbiol.org 7 June 2014 | Volume 10 | Issue 6 | e1003677
recent study of mouse enhancers from different developmental
stages [75]. Finally, we observed that E11.5 heart enhancers have
an unusually high GC content (49%) compared to enhancers of
other tissues at E11.5 (,40%). A simple classifier based solely on
the GC content of a region performs nearly as well as our full
classifier for heart enhancers (Figure S8). In contrast, sequence-
based classifiers do not perform well on the other tissues whose
enhancer GC content is not significantly different from the
genomic background (Table 1). The high GC content of heart
enhancers is not due to overlap with CpG islands. Only about 4%
of VISTA enhancers overlap with a CpG island, and this number
is consistent across tissues. We also did not find enrichment for any
known GC-rich transcription factor binding site motifs in VISTA
heart enhancers. We do see, however, that repeat regions in heart
enhancers are depleted for the very AT-rich repeats seen in other
enhancers, and that most of the repeat regions in heart enhancers
are 40–60% GC. Our results suggest the possible existence of
unknown GC-rich motifs that may be important for gene
regulation in the cardiac lineage.
The heart classifier based on functional genomics data alone
exhibits strong performance compared to other tissue-specific
classifiers as well (Table 1). It is possible that this is due to the
presence of feature data from contexts more relevant to develop-
mental heart activity than to other tissues, rather than unique
attributes of the heart enhancers themselves. Indeed, the highest
weighted features in the heart functional genomics classifier come
from heart tissues. However, the performance of the heart classifier
based only on functional genomics data does not decrease
substantially when we exclude data from the most relevant contexts:
embryonic heart tissue, adult hearts, and stages of a directed
differentiation of stem cells into cardiomyocytes (ROC
AUC=0.85). Thus, it is possible that feature data from less
obviously relevant contexts are more informative about heart
Figure 3. Integrating diverse functional genomics data improves enhancer prediction. (A) Considering functional genomics features from
contexts and assays not directly associated with developmental enhancer activity (All Functional Genomics and Relevant Functional
Genomics) improves the identification of developmental enhancers (p = 9.2E-9 and p= 2.7E-6, respectively, compared to Embryonic Functional
Genomics only). (B) Combining available H3K4me1, p300, and H3K27ac data, which are commonly used in isolation to identify enhancers, in a linear
SVM (Basic Functional Genomics) is better able to distinguish known developmental enhancers from the genomic background than considering
each type of data alone (p,2E-7, for each). However, combining these marks still performs significantly worse than EnhancerFinder (Figure 2A;
AUC= 0.96) and considering additional data as in (A).
doi:10.1371/journal.pcbi.1003677.g003
Figure 4. Enhancers of heart expression are easier to identify
than enhancers active in other tissues at E11.5. (A) In Step 2 of
our prediction pipeline, we trained EnhancerFinder using the same
features as in Step 1 (Figure 1), but using VISTA enhancers active in a
given tissue as positives and tested regions that did not show activity in
the tissue as negatives. Heart enhancers were dramatically easier to
distinguish from other enhancers than enhancers of expression in other
tissues. The heart enhancers have significantly higher GC content than
other enhancers and the genomic background. This and several other
unique attributes may explain the ease of identifying them (Figures S7
and S8). In general, functional genomics data are the most informative
data type for predicting enhancer tissue specificity (Table 1).
doi:10.1371/journal.pcbi.1003677.g004
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activity than for other tissues. We suspect that the ease of
distinguishing heart enhancers may be due to the earlier develop-
ment of the heart compared to other tissues (see Discussion).
We predict more than 80,000 developmental enhancers
across the human genome
One of the main motivations for developing algorithms that can
distinguish active enhancers is to apply them to unannotated
genomic regions to aid the exploration and interpretation of the
gene regulatory landscape of the human genome (Figure 1). To
produce a genome-wide set of candidate developmental enhanc-
ers, we divided the genome into 1.5 kb blocks overlapping one
another by 500 bp and applied Step 1 of EnhancerFinder to each
of these regions. EnhancerFinder produces a score for each region;
positive scores indicate membership in the positive set (enhancers),
and negative scores indicate membership in the negative set (non-
enhancers). To focus on high confidence predictions in this
genome-wide analysis, we used the cross-validation-based evalu-
ation described above to find a 5% FPR score threshold, and only
considered regions exceeding this threshold. After merging
overlapping positive predictions, we identified 84,301 develop-
mental enhancers across the human genome with median length
of 1,500 bp and total genome coverage of 183,695,500 bp
(5.86%).
The 5% FPR threshold we used corresponds to a 65% true
positive rate (TPR). To calculate the false discovery rate (FDR), we
must estimate the unknown fraction of 1.5 kb blocks of the human
genome that harbor developmental enhancer regions. If this
fraction were as high as 50%, a 5% FPR would correspond to a
9% FDR. If instead we estimate that 10% of 1.5 kb windows
contain a developmental enhancer, we see an FDR of 47% at a
5% FPR. While this may seem high, our recent analysis of
predicted enhancers with human-specific substitution rate accel-
eration found a lower failure rate at E11.5 (17%, 5/29) [74], and
only three of ten tested predictions did not validate with confirmed
or suggestive activity in our zebrafish assay (see below). This
suggests that the FDR may be lower in experimental applications,
especially when predicted enhancer regions are analyzed in the
context of other relevant data. However, to accurately measure the
true FDR would require experimental testing of a very large,
random set of EnhancerFinder predictions, which is beyond the
scope of this study.
In our genome-wide analysis, we used the smaller Relevant
Functional Genomics data set in order to reduce the
computational time required. We also did not include evolutionary
Figure 5. EnhancerFinder’s two-step approach captures tissue-
specific attributes of enhancers. (A) The true overlap of human
enhancers of brain, heart, and limb in the VISTA database. The vast
majority of characterized enhancers are unique to one of these tissues
at this stage. For example, of the 84 validated heart enhancers, 71 are
unique to heart, five are shared with brain, four with limb, and four with
both. (B) The predicted overlap of VISTA enhancers based on
predictions made with a single training step using MKL with only
enhancers of that tissue considered positives and the genomic
background as negatives. This approach overestimates the number of
enhancers active in multiple tissues. Each classifier mainly learns general
attributes of enhancers, rather than tissue-specific attributes. (C) The
predicted overlap based on EnhancerFinder’s two-step approach. These
predictions are much more tissue-specific and exhibit overlaps between
tissues similar to the true values (A). Predicted tissue distributions are
similar when the methods are applied to other genomic regions, as
illustrated in our genome-wide predictions, but only predictions on
VISTA enhancers are shown here to enable comparisons to the
distribution for validated enhancers (A).
doi:10.1371/journal.pcbi.1003677.g005
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conservation data, because the positives in our training data are
almost universally conserved. While most enhancers likely exhibit
some evolutionary conservation, this extremely high fraction is
likely due to bias in the selection of the tested regions in VISTA
and could reduce our ability to detect less highly conserved novel
enhancers genome-wide (see Discussion). The resulting conser-
vation-free classifier still performed extremely well in cross
validation (AUC=0.92). Supporting this approach, non-con-
served regions make up over 20% of our genome-wide enhancer
predictions. As noted above, we did not observe any other
dramatic biases in the feature data associated with human VISTA
enhancers.
Next, we applied Step 2 of EnhancerFinder to all enhancer
regions predicted in Step 1. We focused on brain, limb, and
heart, because these tissues are highly represented in VISTA and
have been extensively studied in previous analyses of develop-
mental enhancers. We predicted 7,400 limb enhancers, 19,051
heart enhancers, and 11,693 brain enhancers (Figure 6) at a 5%
FPR threshold tuned separately for each tissue. Since Enhancer-
Finder makes predictions for each tissue independently, there are
no constraints on the distribution of tissues in the resulting
genome-wide predictions. Nonetheless, we find a high level of
tissue-specificity; nearly 90% of the limb, heart, and brain
enhancers are predicted to be active in just one of the three
tissues.
All genome-wide enhancer predictions are available as tracks
for import into the UCSC Genome Browser (Data File S1).
These lists of high-confidence tissue-specific enhancers should
not be viewed as exhaustive; we found thousands of regions
with positive, but less significant scores from Step 2 of
EnhancerFinder.
Predicted enhancers are associated with relevant
functional genomic regions
To characterize and further validate our genome-wide enhancer
predictions, we examined their genomic distribution with respect
to several independent indicators of function (details in Text S1).
Genes near brain and heart enhancers are enriched for expression
in relevant tissues (Tables S2 and S3). Similarly, Gene Ontology
(GO) Biological Process enrichment analyses of nearby genes
suggest that our predicted developmental enhancers target genes
that function in relevant cell types and tissues (Figure 6). The most
prevalent transcription factor binding site motifs found in the
sequences of predicted enhancers differed between enhancers of
different tissues and included many relevant developmental TFs
(Table S4). Finally, our predicted enhancers contain 676 lead
SNPs associated with significant effects in GWAS (Table S5); this
is significantly more than expected at random (permutation p,
0.001).
Taken together, these analyses suggest that EnhancerFinder
identifies many active regulatory regions that contain functionally
relevant variation. Our tissue-specific enhancer predictions give
valuable annotations to thousands of non-coding regions of the
human genome that had not previously been linked to develop-
Figure 6. Predicted tissue-specific enhancers exhibit tissue-specific characteristics. EnhancerFinder identifies thousands of novel high-
confidence (FPR,0.05) heart, brain, and limb enhancers. These enhancers are enriched for tissue-specific GO Biological Processes. The five most
enriched GO Biological Processes among genes near each enhancer set (as calculated using GREAT) are listed in the colored boxes. Nearly 90% of
EnhancerFinder predicted heart, brain, and limb enhancers are unique to a single tissue. The larger number of high-confidence heart enhancers
relative to brain and limb enhancers is the result of the superior performance of the heart classifier.
doi:10.1371/journal.pcbi.1003677.g006
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mental regulation. For example, thousands of SNPs associated
with disease by GWAS are in non-coding regions with limited
functional annotations [76]. Our genome-wide enhancer predic-
tions provide a resource for exploring the mechanisms and
functional effects of these uncharacterized GWAS hits.
EnhancerFinder predictions function as enhancers in the
developing embryo
To demonstrate that genome-wide EnhancerFinder predictions
can facilitate the discovery of functional regulatory elements, we
present two case studies in which we identify and validate novel
enhancers near genes active during development.
EnhancerFinder identifies many novel enhancers near
FOXC1 and FOXC2. To evaluate several EnhancerFinder
predictions, we took advantage of a transgenic enhancer assay
in embryonic zebrafish (Methods). We tested enhancer activity of
ten predicted human enhancers near FOXC1 and FOXC2, two
forkhead box TFs. The mouse homologs Foxc1 and Foxc2 have
been studied extensively and have been shown to be required for
proper embryonic development; Foxc1 null and Foxc2 null
mutants are pre- or perinatal lethal [77,78,79]. In humans,
complete lack of FOXC1 is also typically pre- or perinatal lethal,
and deletions near and point mutations in FOXC1 contribute to
eye and brain development disorders [80,81]. Figure 7 shows the
genomic context of FOXC2, along with the candidate enhancers
that we tested (FOXC2 Enhancer Candidates, or F2ECs). FOXC1
results are shown in Supplementary Figure S10 (FOXC1
Enhancer Candidates, or F1ECs). Six of the ten predicted
human enhancer sequences showed consistent enhancer activity
in zebrafish at 24 or 48 hours post fertilization (hpf) (F1EC-1,
F1EC-6, F2EC-1, F2EC-2, F2EC-3, and F2EC-4). One addi-
tional candidate enhancer (F1EC-3) showed suggestive enhancer
activity. EnhancerFinder predicted tissue specificity for eight of
the ten candidate enhancers, and we saw the predicted
expression pattern confirmed for just one candidate enhancer
(F2EC-3, predicted heart enhancer), and suggestive expression
for another (F1EC-6, predicted heart enhancer). However, it is
difficult to interpret this result, since the tested stages (24 and
48 hpf) do not directly correspond to single stages of mammalian
development, and some of the studied tissues are not homolo-
gous. Also, since we tested predicted human enhancer sequences
in zebrafish, it is possible that differences in developmental
regulation between human and fish contributed to this result.
EnhancerFinder predictions highlight a novel enhancer
near ZEB2. Next, we sought to investigate a novel enhancer
prediction in a mammalian system. We selected the locus
containing ZEB2, a zinc finger E-box-binding homeobox-2 TF,
which has many roles throughout embryonic and postnatal
development, in particular in cortical neurogenesis
[82,83,84,85]. Mutations in ZEB2 are associated with Mo-
wat-Wilson syndrome, a complex developmental disorder [86].
However, relatively little is known about the genetic mecha-
nisms that orchestrate ZEB2’s expression. A long-range
enhancer of postnatal expression in developing kidney cells
(E1 in Figure 8) was recently discovered 1.2 megabases (Mb)
downstream of ZEB2 in the adjacent gene desert [87]. Since
this enhancer does not fully recapitulate the expression timing
and domains of ZEB2, the authors speculated that the gene has
many other, potentially long-range, enhancers. Supporting this
theory, there are two validated E11.5 brain enhancers near
ZEB2 in the VISTA Enhancer Browser (Figure 8, VISTA
hs407 and VISTA hs1802). Finally, there is an enrichment of
human accelerated regions (HARs) [88,89] near ZEB2,
suggesting that it may have human-specific regulatory patterns.
Our EnhancerFinder predictions support the existence of a rich
regulatory program specified in the non-coding sequence nearby
ZEB2; there are 54 predicted enhancers for which it is the nearest
TSS. This puts ZEB2 in the top 0.2% of all genes with respect to
Figure 7. Four novel developmental enhancers near FOXC2. This UCSC Genome Browser (http://genome.ucsc.edu) snapshot shows the
genomic context of four candidate human enhancers tested in transgenic zebrafish. For each enhancer, we show a zebrafish image that is
representative of the reproducible expression patterns. FOXC2 Enhancer Candidate 1 (F2EC-1) drives expression at 48 hpf in the eye and epidermis
(arrows). F2EC-2 shows expression at 24 hpf in the forebrain, midbrain, and nerve. F2EC-3 drives expression at 48 hpf in the epidermis and heart.
F2EC-4 shows expression at 48 hpf in the notochord, spinal cord, and heart. See Table S6 for full list of expressed tissues seen in each candidate
enhancer and Figure S10 for results on candidate enhancers near FOXC1.
doi:10.1371/journal.pcbi.1003677.g007
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the number of adjacent enhancer predictions. Supporting the
validity of our predictions, the known VISTA enhancers both
overlap EnhancerFinder predicted enhancers, while the regions
known to be inactive or active at later postnatal developmental
stages (E1) [87] do not
We selected an EnhancerFinder predicted enhancer (indicated
in the zoomed pane of Figure 8) for further experimental analysis
due to its high EnhancerFinder score and overlap with a HAR
(2xHAR.240). We interrogated the potential of the human and
chimp sequences at this region to drive gene expression at E11.5 in
transient transgenic mouse embryos. All seven embryos with
staining showed cranial nerve expression (Figure 8 red box; Figure
S11), regardless of whether the construct contained the human or
chimp sequence. Thus, we have identified a novel enhancer within
the ZEB2 locus that overlaps one of its expression domains;
however, whether this enhancer targets ZEB2 remains to be
proven.
This is not the only HAR enhancer validated to date. In a
recent publication, we showed that many HARs function as
developmental enhancers [90]. In that study, we experimentally
tested 29 HARs that EnhancerFinder predicts to function as
developmental enhancers, and found, in agreement with the cross-
validation and zebrafish experimental validation rates here, that
24 of the regions (83%) show positive enhancer activity at E11.5.
In addition, one EnhancerFinder negative showed no enhancer
activity.
While none of the enhancer predictions tested so far were
randomly selected, our results suggest that EnhancerFinder is a
powerful tool for accurately characterizing developmental regula-
tory potential in many useful contexts. Our enhancer predictions
highlight many additional candidates for further investigation, and
we believe that they will enable similar analyses of the regulatory
potential of many other genes and regions of interest.
Discussion
In this study, we developed EnhancerFinder, a new machine-
learning framework for predicting regulatory enhancers from
diverse data sources. In contrast to most previous enhancer
identification strategies, which have based their predictions on one
or a small number of data types, EnhancerFinder enables us to
flexibly integrate the large and continually expanding collection of
evolutionary, DNA sequence, and functional genomics data that
are informative about enhancer function. Our analysis of the
EnhancerFinder algorithm and its predictions makes three major
contributions. First, we demonstrate that integrating diverse types
of data from many cellular contexts, including some unexpected
ones, can accurately predict in vivo validated developmental
Figure 8. A novel cranial nerve enhancer in the ZEB2 locus. This UCSC Genome Browser snapshot shows a dense region of predicted
enhancers in a 1.5 Mb window on human chromosome 2 including ZEB2 and part of the adjacent gene desert. Tracks give the locations of four
human accelerated regions (HARs), two validated VISTA enhancers (hs407 and hs1802), and the E1 region recently shown to have postnatal enhancer
activity [87]. The inset shows a zoomed in view of ZEB2 (hg19.chr2:145,100,000–145,425,000) along with summaries of several ENCODE functional
genomics datasets and evolutionary conservation across placental mammals. We tested the predicted enhancer overlapping 2xHAR.240 for enhancer
activity at E11.5 in transgenic mice. Both the human and chimp versions of this sequence drive consistent expression in the cranial nerve (Figure S11).
doi:10.1371/journal.pcbi.1003677.g008
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enhancers. Second, we show that a two-step approach in which
enhancer tissue-specificity is individually evaluated after general
enhancer prediction improves the identification of enhancers’
tissues of activity. Finally, our genome-wide developmental
enhancer annotations, including tissue-specific predictions for
heart, brain, and limb, assign novel functions in development to
thousands of genomic regions. We show that these predictions are
enriched for a number of independent indicators of regulatory
functions. As a result, we expect our predictions to prove useful in
the annotation of non-coding genomic regions, as illustrated in the
identification of novel enhancers near ZEB2, FOXC1, and FOXC2.
Our genome-wide predictions are freely available as a UCSC
Genome Browser track.
A biologically active in vivo definition of ‘‘enhancer’’
We chose to define developmental enhancers for training as
genomic regions that are experimentally shown to activate gene
expression in vivo in embryonic mouse assays. We believe that this
definition is better suited to identifying regions for further
exploration and experimental characterization than approaches
based on single data sources, such as p300, H3K4me1, or
H3K27ac, associated with enhancers in individual cell lines. We
showed that our predicted enhancers, based on this biologically
active definition, significantly overlap data sets commonly used as
proxies for enhancer activity, such as H3K27ac and p300 binding.
However, these other data alone are not sufficient to identify all
enhancers, as we demonstrated for H3K27ac, H3K4me1, and
p300 in Figure 3B. Similarly, when we evaluated the ability of
other computational methods to identify enhancers, we find that
they perform better than random, but that EnhancerFinder
significantly outperforms them at identifying biologically active
developmental enhancers. This is not surprising given the different
contexts in which some enhancer predictions, such as those from
ChromHMM and Segway, were developed.
While EnhancerFinder could be used to predict enhancers in
well-characterized cell lines, it is particularly useful at identifying
enhancers in complex tissues that contain multiple cell types and in
cell types that do not have much specific functional genomics data
available. Other computational approaches to enhancer prediction
have focused on identifying enhancers in individual cell types using
functional genomics data from the same cells [56] or using the
differences in cell type specific transcription factor binding to
identify cell-type specific binding motifs [61]. These methods
generally perform well, but they do not address enhancer
prediction in cell types with little or no functional genomics data,
or in tissues that contain multiple cell types.
Why do seemingly irrelevant data improve our enhancer
predictions?
Data such as p300 binding sites and H3K4me1 have been used
in previous studies to identify enhancers, and these data are major
contributors to our enhancer predictions. However, data from
other sources and contexts less directly associated with enhancer
activity provide complementary information that improves our
predictions. Some of these data may be negatively correlated with
enhancer activity, allowing EnhancerFinder to learn what features
distinguish regions that are not developmental enhancers. Others
may help reinforce patterns present in data from more relevant
contexts, reflecting some degree of stability in the features of
enhancer regions across developmental stages and cell types. For
example, we found that features measured in embryonic stem cells
are quite useful for E11.5 enhancer prediction; their removal from
the classifier degrades performance and/or they have large
(positive or negative) MKL weights. Examination of these features
suggests that some identify ‘‘poised’’ regions that will become
active enhancers upon differentiation, while others seem to help
distinguish stem cell enhancers (i.e., non-enhancers at E11.5) from
those specific to differentiated lineages. We note that despite these
interesting observations, most individual functional genomics
features do not carry a great deal of information and the power
of EnhancerFinder comes from the integration of different types of
data. It is also possible that as a more complete experimental
characterization of chromatin state and protein-DNA binding
from E11.5 tissues is obtained, data from less relevant contexts will
not provide as much improvement as it did in this study.
What data are most informative about enhancer activity?
We focused on a single developmental stage with a large
number of validated enhancers. To efficiently extend enhancer
detection and validation to new contexts, it will be very important
to select the most informative data to collect. Even though the
ENCODE project has produced an impressive amount of data, it
still has not extensively assayed most contexts of interest to
researchers, in particular developmental biologists. The perfor-
mance of classifiers trained on subsets of all our data and the
weights we learned for feature sets and individual features provide
some guidance for future experiments. Evolutionary conservation
and DNA sequence patterns are broadly useful in the identifica-
tion of enhancers, but our results suggest that adding functional
genomics data is necessary to make more precise predictions about
the contexts of activity. H3K4me1 and p300 are two of the most
useful functional genomics data types overall (Figure S6), but many
others are useful in particular contexts. However, the non-random
sampling of functional genomics data and enhancers makes
definitively determining the relative utility of different data types
challenging.
Why are heart enhancers easier to predict than other
types of enhancers?
We saw a broad range in our ability to predict the tissue
specificity of enhancers from existing data. Heart enhancers were
dramatically easier to identify than other tissue-specific enhancers.
Heart enhancers have significantly higher GC content than
enhancers of other tissues, are less evolutionarily conserved, and
are closer to the nearest TSS than other known enhancers at
E11.5, and we show that GC content alone is sufficient to
accurately predict many heart enhancers (Figures S7 and S8).
However, functional genomics data alone were also able to
accurately predict heart enhancers. The underlying biological
explanation for these patterns may have to do with relative
developmental age of different organs and tissues. At E11.5, the
heart is further along its developmental trajectory than the other
tissues considered, and heart enhancers have completed their most
conserved developmental stage, whereas forebrain enhancers are
most strongly conserved at E11.5 and E14.5 [75]. At E11.5, many
of the less conserved, mammal-specific features of the heart are
developing [91,92], whereas other tissues are still developing under
more general, less species-specific conserved regulatory programs
at E11.5 [93]. A recent study of enhancers in the adult mouse
retina found that high local GC content was strongly correlated
with enhancer activity [94]. Paired with our result, this suggests
that GC content is a distinguishing feature of certain classes of
enhancers.
Limitations of our approach
In spite of the strong overall performance of EnhancerFinder at
predicting tissue-specific developmental enhancers, our approach
Integrative Developmental Enhancer Prediction
PLOS Computational Biology | www.ploscompbiol.org 13 June 2014 | Volume 10 | Issue 6 | e1003677
has some limitations. First, we rely heavily upon the VISTA
Enhancer Browser for training examples, because it is the largest
collection of validated mammalian enhancers currently available.
This resource provides an impressive catalog of validated human
regulatory enhancers, but it is limited to a single developmental
stage and experimental system. Without more data and analysis, it
is difficult to evaluate how specific our predictions are to this
context. Applying EnhancerFinder to known enhancers in model
organisms, such as zebrafish and fly, would provide additional
opportunities to evaluate our approach and findings, while
potentially demonstrating differences in how enhancers function
in these different species.
Second, most of the enhancers present in VISTA are
evolutionarily conserved. As a result, the VISTA enhancers
cannot be viewed as an exhaustive catalog of the full range of
enhancers. However, these regions have validated enhancer
activity in vivo, and thus provide an appealing alternative to
approaches that use single-mark proxies for enhancer activity (e.g.,
considering all H3K27ac peaks as active enhancer regions). In
addition to being conserved, these regions contain many signatures
of enhancers in their sequence motifs and functional genomics
composition that are useful for predicting enhancers. To
emphasize these features and mitigate the impact of bias towards
conserved regions, we removed evolutionary conservation as a
feature from EnhancerFinder when we applied it to predict
enhancers genome-wide. Our goal in doing so was to improve our
ability to discern less conserved enhancers in these genome-wide
predictions, and indeed, we predicted thousands of non-conserved
enhancers (,20% of all predictions).
Third, though our predictions are based on a large collection of
genome-wide chromatin state, protein-binding, and sequence
information from many contexts, we are still limited by data
availability. Even with the impressive efforts of ENCODE and
related projects, producing data that are perfectly matched to all
contexts of interest is time consuming and sometimes impossible,
especially when studying humans. Thus, it will be important to
develop a principled understanding of how different data can be
generalized across tissues, developmental stages, and between
species. In our analysis, many of the highest weighted features
come from contexts close to the developmental stage of interest,
and thus we anticipate that gathering more data from develop-
mentally relevant cells and tissues will significantly improve our
ability to annotate genomic regions involved in the regulation of
embryonic development. However, data from other, seemingly
unrelated, contexts may continue to prove useful.
Extensions and future applications
This study annotates regulatory elements in the human
genome and provides tools for interpreting the effects of
mutations in non-coding regions. Our case studies on regions
around ZEB2, FOXC1, and FOXC2 illustrate how our
predictions can facilitate the rapid identification of novel
enhancers. In addition, the statistical enrichment for GWAS
SNPs in our genome-wide enhancer predictions suggests that
they may be a good resource for pinpointing causal mutations
in potential disease loci.
EnhancerFinder is a general framework for enhancer prediction
and evaluation of different data sources that aim to annotate the
regulatory functions of the human genome. It could easily be
extended to include additional types of data, such as population-
level variation at each locus, information about the three-
dimensional state of the genome from Hi-C and 5C, and
predictions of potential target genes for each enhancer. It could
also be used to analyze additional aspects of the data we already
consider, such as accounting for the relative genomic position of
different features [66].
The EnhancerFinder two-step approach enables delineation of
features common to all enhancers versus those that characterize
enhancers of different types. For example, we find that predicting
enhancers that are unique to a single tissue is more difficult than
those that are active in multiple tissues (Figure S9), that certain
features make prediction of heart enhancers particularly easy, and
that different features are selected in classifiers for general
enhancers and those for specific tissues. Together, these results
suggest that there may be distinct classes of enhancers, even
among those active in a given tissue at a single developmental
stage. Further analysis of EnhancerFinder classifiers based on
different types of data may help suggest biological mechanisms
underlying the functional distinctions and genomic features of
these different classes of enhancers.
Methods
Ethics statement
Transgenic mice were generated by Cyagen Biosciences
(http://www.cyagen.com/). Their facility meets and often
exceeds animal health and welfare guidelines. Animals were
euthanized using techniques recommended by the American
Veterinary Medical Association. All procedures were carried
out in line with Gladstone Institutes and University of
California guidelines. All zebrafish work was approved by
the UCSF Institutional Animal Care and Use Committee
(protocol number AN100466).
Genomic data
All work presented in this paper is based on the February 2009
assembly of the human genome (GRCh37/hg19) downloaded
from the UCSC Genome Browser (http://genome.ucsc.edu/).
Any data that was not in reference to this build was mapped over
using the liftOver tool from the UCSC Kent tools (http://
hgdownload.cse.ucsc.edu/admin/jksrc.zip).
Multiple kernel learning-based prediction of
developmental enhancers
In our framework, genomic regions are associated with a
common set of descriptive features. We then apply machine-
learning algorithms that use the features of known training
examples to learn a function of the feature data that distinguishes
the positives (enhancers) from the negatives (non-enhancers). This
function can then be applied to the features associated with
uncharacterized genomic regions to predict their enhancer status.
A positive score for a genomic region indicates predicted
membership in the positive class (enhancers) and a negative score
indicates predicted membership in the negative class (non-
enhancers).
Training examples. We obtained all of our positive training
data and our tissue-specific negative training data from the VISTA
Enhancer Browser [69] on April 4, 2012. We downloaded the
location, DNA sequence, and expression contexts for all human
sequences tested in the VISTA mouse E11.5 enhancer screen.
This consisted of 711 validated human enhancers and 736
genomic regions that did not exhibit enhancer activity in this
context (http://enhancer.lbl.gov/). The median length of the
enhancers in VISTA is 1,545 bp.
In the first step of EnhancerFinder (Figure 1), we used all 711
VISTA enhancers as positive training data. For negative training
data, we generated a set of 711 random genomic regions matched
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to the length and chromosome distribution of the positives, and
filtered to remove known VISTA enhancers and assembly gaps.
In the second step of EnhancerFinder, we used tissue-specific
subsets of the 1,447 VISTA regions for training. For example,
when predicting heart enhancers, our positive training data were
the 84 VISTA regions with heart expression in E11.5 mice, and
our negative training data were the remaining 1,363 VISTA
regions that were tested and showed no heart expression at E11.5,
even though they may be enhancers in other tissues or none at all.
We did not require that a region be active only in the tissue of
interest. We included the VISTA negatives in this analysis,
because they share many attributes in common with known
enhancers and may have enhancer activity in contexts other than
E11.5. Our results did not change dramatically when the VISTA
negatives were not included in the training. We trained tissue-
specific classifiers for the six tissues with more than 50 examples in
VISTA: forebrain, midbrain, hindbrain, heart, limb, and neural
tube. We also trained a brain enhancer classifier on the combined
the forebrain, midbrain, and hindbrain enhancers.
Feature data. We considered three main types of data as
features in our analysis: functional genomics data, evolutionary
conservation, and DNA sequence motifs. We obtained our
functional genomics feature data from the ENCODE data
repository at the UCSC Genome Browser (http://genome.ucsc.
edu/ENCODE/ and [95]). These data include histone modifica-
tions, such as H3K4me1, H3K4me3, H3K27ac, protein-DNA
associations for many TFs and p300, and several measurements of
open chromatin (DNaseI hypersensitivity, FAIRE, digital genomic
footprinting), from hundreds of cell types [95]. We also included
heart p300 data from [39]. For a full list of the functional genomics
data considered, see Table S1. We associated each genomic region
with a binary vector that represents the presence or absence of
overlap with each functional genomics data set. To determine this
feature vector, we intersected the genomic location of the region of
interest with the peaks defined by the original researchers (from
the broadPeak or narrowPeak files) using intersectBed [96]. We
found that considering non-binary functional genomics features
based on experimental data, like the density of sequence reads
from a ChIP-seq study, did not significantly improve performance
(data not shown). However, we suspect that with consistent peak
calling and appropriate normalization this might be an avenue for
future improvement.
To summarize the DNA sequence motif patterns in a genomic
region, we calculated the number of occurrences of all possible 4-
mers in the sequence.
Evolutionary conservation estimates were taken from the
mammalian phastCons elements [72] obtained from the phastCon-
sElements46wayPlacental track in UCSC Genome Browser. Each
genomic region was assigned its maximum overlapping phastCons
score or zero if it did not overlap any phastCons elements.
Machine-learning algorithms. EnhancerFinder is an ex-
tension of the SVM supervised learning framework that allows the
integration of multiple data types into a single discrimination
function. Standard 1-norm MKL augments the usual SVM
discrimination function, f, with additional parameters, bj, that
weight the contribution of each kernel function kj:
f (x)~
XN
i~1
ai
XM
j~1
bjkj(x,xi)zb
where N is the number of training examples, M is the number of
kernels, ai are the training example weights, and b is the bias [66].
We include three kernel functions in EnhancerFinder, each of
which corresponds to one of the three types of feature data
described above. These kernels quantify the similarity of the
features of the appropriate type for any two genomic regions. To
combine the kernels, the MKL algorithm simultaneously learns
weights for the associated kernels, in addition to learning the bias
and weights for each training example as in a standard SVM. We
use the 4-spectrum kernel [71] for our sequence features; this
kernel has been shown to perform well in a variety of DNA
sequence-based prediction tasks including enhancer prediction
[54]. For the functional genomics and evolutionary conservation
data, we use linear kernels, which are equivalent to dot products of
the feature vectors. We explored the use of alternative, non-linear
kernels for these features and found that they performed similarly
(data not shown). Each kernel was variance normalized, and we
balanced the misclassification costs by class size [97]. In addition
to EnhancerFinder classifiers, we also trained and evaluated the
constituent single kernel SVMs. All analyses were performed using
the implementation of SVMs and MKL in the SHOGUN
Machine Learning Toolbox v1.1.0 [98].
Performance evaluations
To evaluate the performance of trained classifiers, we
performed 10-fold cross-validation on the training data and
quantified our results with ROC AUC, precision-recall curves,
and power estimates at fixed false positive rates. We computed p-
values for the difference in performance between classification
methods using McNemar’s test [99,100]. To estimate false
discovery rates, we trained EnhancerFinder classifiers at 1:1,
1:10, and 1:100 ratios of positive to negative enhancers and used
the resulting 10-fold cross-validation results to calculate the
proportion of false discoveries genome-wide at a 5% FPR if the
true proportion of 1.5 kb windows containing an enhancer was
50%, 10%, or 1%.
Comparison to existing enhancer prediction methods
We compared EnhancerFinder’s predictions to those of several
previous enhancer prediction methods. We obtained the perfor-
mance of CLARE on our Step 1 prediction task, by inputting our
positive and negative data into the CLARE web server [73]. We
downloaded the genomic segmentations and annotations pro-
duced by ChromHMM [64] and Segway [65]. We considered the
ChromHMM predictions based on different ENCODE cell lines
both individually and together. Any genomic region in our
evaluation data set that overlapped an enhancer state was
considered a predicted enhancer, and all others were considered
predicted non-enhancers. For Segway, we also considered the ‘‘TF
activity’’ state.
Identification of tissue-specific enhancers across the
human genome
We predicted tissue-specific developmental enhancers through-
out the human genome by applying a trained MKL classifier (Step
1 of EnhancerFinder) without conservation (see Results) to sliding
windows of 1500 bp, moving along the human genome in 500 bp
steps. The feature profile for each window was computed as
described above. To focus on high-confidence predictions, we
filtered the enhancer scores for the windows at a 5% FPR,
estimated from cross-validation using the genomic background,
and combined the remaining overlapping windows to produce
84,301 high-confidence predicted enhancers.
To predict tissue specificity, we applied trained brain, limb, and
heart classifiers (Step 2 of EnhancerFinder) without conservation
to all 299,039 windows with positive enhancer scores in Step 1. We
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then applied a 5% FPR cutoff for each tissue and concatenated the
remaining overlapping windows into merged enhancer regions.
Using this approach, we predicted 19,051 heart enhancers, 11,693
brain enhancers, and 7,400 limb enhancers.
Analysis of genome-wide tissue-specific enhancer
predictions
We characterized the expression patterns of the gene nearest to
each predicted enhancer using the GNF Atlas 2 [101]. It contains
expression data for genes in 79 different tissues, with expression
measured using Affymetrix microarrays. For each of these 79
tissues, we used a paired t-test to determine if the nearest genes of
predicted heart enhancers had significantly different mean values
of expression than the nearest genes of brain enhancers. We did
not include the limb enhancers in this analysis due to the lack of
relevant expression data in the GNF Atlas 2.
We examined genomic regions near predicted developmental
enhancers for enrichment of Gene Ontology functional annota-
tions, known phenotypes, and pathways using GREAT [102].
Results were computed using the hypergeometric test for genome-
wide significance, with the default settings and the ‘‘basal plus
extension’’ association rule (proximal 5 kb upstream, 1 kb
downstream, plus distal up to 100 kb).
We identified the sequence motifs present in each set of
enhancers using the FIMO tool (Find Individual Motif Occur-
rences) from the MEME Suite of sequence motif analysis tools
[103]. We considered known transcription factor binding motifs
from the April 2011 release of the TRANSFAC database with a
FIMO score threshold of 10e-5. We identified those occurrences
that fell in predicted enhancers, and summarized motifs to identify
the most prevalent TFs in each tissue-specific set of enhancers.
We analyzed the overlap of predicted enhancers with GWAS
SNPs, based on the NHGRI catalog of 9,687 GWAS SNPs
downloaded from the UCSC Genome Browser in October 2012.
Unadjusted permutation p-values were calculated by randomizing
genomic locations of predicted enhancers (matching for length and
chromosome, and avoiding assembly gaps) and overlapping these
randomized regions with GWAS SNPs to assess significance of
overlapping regions.
Transgenic enhancer assays
Mouse enhancer assays were carried out in transient transgenic
mouse embryos generated by pronuclear injections of enhancer
assay constructs into FVB embryos (Cyagen Biosciences). Human
and chimpanzee DNA sequences were inserted upstream of a
minimal promoter Hsp68 and a LacZ reporter gene. The human
sequence was amplified using primers 59-TGTAT-
GAAACCTGTTCACTCTCC-39 and 59-GCTTAAAACAAC-
TACTAGAATCAGGC-39 from the bacterial artificial chromo-
some (BAC) RP11-107E5 (from the BacPac resource at CHORI).
The chimpanzee sequence was amplified using primers 59-
TGTATGAAACCTGTTCACTCTCC-39 and 59-GCTTAAAA-
CAACTACTAGAATCAGGC-39 from BAC CH251-677E03a
(CHORI). The embryos were collected and stained for LacZ
expression at E11.5.
Following the annotation policies of the VISTA Enhancer
Browser, we required that consistent spatial expression patterns be
present in three or more embryos with staining in order for the
region to be considered an enhancer.
Zebrafish enhancer assays were performed in transient trans-
genic zebrafish embryos. We tested candidate enhancer regions
that ranged in length from 987 bp to 3,633 bp (see Table S6 for
hg19 genomic coordinates), which we manually demarcated from
within larger predicted enhancer regions based on signatures of
likely enhancer function (including DnaseI hypersensitivity sites,
transcription factor binding sites, histone modifications, and
conservation).
We performed PCR to obtain the candidate enhancer sequence
using human genomic DNA (Roche). These were cloned into the
E1b-GFP-Tol2 enhancer assay vector containing an E1b minimal
promoter followed by GFP [104], and the construct was verified
by sequencing. Each construct was injected with Tol2 mRNA into
at least 100 single-cell fertilized zebrafish embryos. We annotated
GFP expression at approximately 24 and 48 hours post fertiliza-
tion (hpf), and considered an enhancer to be positive if we
observed consistent expression in at least 15% of all fish alive at
either 24 or 48 hpf [105], and suggestive of enhancer activity if we
observed consistent expression in at least 10% of all fish alive at 24
or 48 hpf, after subtracting out percentages of tissue expression in
fish injected with the empty enhancer vector. For each construct,
at least 50 fish were analyzed for GFP expression at 48 hpf.
Supporting Information
Figure S1 Precision-Recall curves corresponding to all
ROC curves presented in the main text. (A) Figure 2A (B)
Figure 3A (C) Figure 3B (D) Figure 4. A PR curve could not be
created for Figure 2C, because we could not obtain the raw scores
for regions from the CLARE web server.
(PDF)
Figure S2 VISTA enhancers overlap many common
marks of enhancers, but no common mark is universal
to all VISTA enhancers. We computed the overlap between
711 VISTA enhancers and three common functional genomic
marks of enhancers and found that 450 enhancers overlap
H3K27ac (in any of 16 datasets from ENCODE), 563 overlap
H3K4me1 (in any of 15 datasets from ENCODE), and 404
overlap p300/CBP (in any of 35 datasets from ENCODE and
human tissues). Fewer than half of the enhancers (306) overlap all
three common marks of enhancers, and 93 do not overlap any of
those three functional genomics marks. All but five of the VISTA
enhancers overlap a conservation peak (phastCons 46-way
placental mammal). Four of these non-conserved enhancers
overlap all three functional genomics marks, and one non-
conserved enhancer overlaps just H3K27ac and H3K4me1.
(PDF)
Figure S3 The 4-spectrum kernel performs competi-
tively with other k-spectrum kernels and the combina-
tion of k-spectrum kernels. We analyzed the ability of
spectrum kernels based on k-mer lengths between 2 and 8 to
distinguish enhancers from the genomic background (Step 1). K-
mers between 4 and 7 had the best performance. We also
evaluated an MKL algorithm that combined each k-spectrum
kernel, and it did not provide significant improvement over the
best individual kernels.
(PDF)
Figure S4 Considering known TFBS motifs does not
improve the 4-spectrum kernel. Considering the number of
occurrences of known TFBS motifs as features has recently been
used in a linear SVM framework to predict enhancers [52]. To
evaluate the utility of this approach, instead of and in addition to
considering all k-mers, we created a linear SVM that used the
number of hits to 1022 TF binding site matrices from
TRANSFAC and JASPAR as computed by FIMO as features.
That is the feature vector for each region consisted of 1022
elements, each of which was the number of significant hits for a
different TF motif. This TFBS linear SVM (AUC=0.81) did not
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perform as well as the 4-spectrum kernel (AUC= 0.88). We also
evaluated an MKL algorithm that combined the 4-spectrum and
TFBS kernels. This combined kernel did not perform any better
than the 4-spectrum kernel suggesting that, at least under this
encoding, TFBS motifs do not provide significant additional
benefit in distinguishing enhancers from the genomic back-
ground.
(PDF)
Figure S5 Combining functional genomics data with an
SVM outperforms simply considering regions overlap-
ping these data. The four solid lines shown are the same as in
Figure 3B; they summarize the performance of these methods at
distinguishing VISTA enhancers from the genomic background
(Step 1). The X’s give the performance of approaches that consider
all regions overlapping a given feature as positives and all others as
negatives. The + and * indicate the performance obtained by
considering the union and intersection of H3K4me1, p300, and
H3K27ac, respectively. For each feature, the linear SVM achieves
better performance than simply considering all overlapping
regions as positives.
(PDF)
Figure S6 EnhancerFinder feature weights highlight the
contribution of different functional genomics data types
to enhancer predictions. Each ‘‘+’’ represents the contribution
made by a single data feature, e.g. H3K4me1 peaks from
embryonic stem cells, to the classification in EnhancerFinder Step
1 (developmental enhancers versus genomic background). Positive
weights (red) indicate an association with enhancer activity in our
analysis and negative weights (blue) suggest a lack of enhancer
activity. The features plotted here come from a range of likely
relevant contexts (Relevant Functional Genomics classifier;
Table S1), and the number of data sets present for each feature
type is given in parentheses. The black bar gives the average
weight over all features of each type. In general, the features with
high average weights, such as H3K3me1, p300, and H3K4me2,
are known to be associated with enhancers, while those with large
negative weights are associated with other types of genomic
regions. However, no data type has uniformly positive or negative
weights in all contexts.
(PDF)
Figure S7 Heart enhancers are less conserved and
closer to the nearest transcription start site (TSS) than
limb and brain enhancers. Considering only limb and brain
enhancers that are less evolutionarily conserved and close to a TSS
improved our ability to identify them, but they are still more
difficult to identify than heart enhancers. In addition to these
features, heart enhancers have uniquely high GC content
compared to other enhancers and the genomic background
(Figure S7).
(PDF)
Figure S8 The uniquely high GC content of heart
enhancers in VISTA enables accurate classification.
The VISTA heart enhancers have higher GC content (49%) than
other types of enhancers and the genomic background (,40%).
(A) The classification score from a spectrum kernel classifier
trained to distinguish heart enhancers within VISTA (Step 2) is
strongly correlated (Pearson rho= 0.95) with the GC content of
the input region. (B) A classification algorithm based solely on GC
content (black) performs competitively with the spectrum kernel
(AUC of 0.80 vs. 0.82), and nearly as well as EnhancerFinder
(0.85; Figure 4).
(PDF)
Figure S9 Enhancers active in multiple tissues are
easier to identify than those active in a single tissue.
There are 399 enhancers active in a single tissue at E11.5 in the
VISTA database and 312 active in multiple tissues. EnhancerFin-
der is better able to distinguish the enhancers active in multiple
tissues from the VISTA negatives (AUC=0.75) than it is to
distinguish single tissue enhancers from the negatives
(AUC=0.67). This trend also holds across each tissue individually.
However, both sets are easy to distinguish from the genomic
background (AUC=0.96 for both, not shown).
(PDF)
Figure S10 Three novel developmental enhancers near
FOXC1. This UCSC Genome Browser screenshot shows six
candidate enhancer regions tested in transgenic zebrafish. Three
of the regions showed positive or suggestive expression at 24 or
48 hpf. F1EC-1 drives expression at 48 hpf; the arrows highlight
reproducible midbrain, spinal cord, and epidermis expression.
F1EC-3 shows suggestive expression at 24 hpf in somitic muscles
and the epidermis (arrows). F1EC-6 drives expression at 48 hpf in
the pericardium and heart (suggestive). The other three tested
candidate enhancers without corresponding zebrafish images were
negative in the enhancer assay. See Table S6 for full list of
expressed tissues seen in each candidate enhancer.
(PDF)
Figure S11 Transient transgenic mouse embryos sup-
port a novel cranial nerve enhancer near ZEB2. Seven
transient transgenic mouse embryos showed LacZ expression at
embryonic day 11.5. Constructs containing a 999 bp region
(hg19.chr2:145,234,541–145,235,539) including 2xHAR.240
near ZEB2, a minimal promoter, and LacZ were used for
human. The orthologous region was used in the chimp construct
(panTro2.chr2b:148,811,929–148,812,929). Three embryos
with constructs containing the human version of the region of
interest and four embryos containing the chimp sequence had
staining. In all embryos, there was consistent expression in the
cranial nerve. There does not appear to be a significant
difference in the activity driven by the human and chimp
sequences at this time point.
(PDF)
Table S1 Functional genomics features used in our
analysis. This Excel spreadsheet lists the files used from
ENCODE (http://genome.ucsc.edu/ENCODE/) or GEO
(http://www.ncbi.nlm.nih.gov/geo/). There is a sheet for each
of the classifiers based on functional genomics data that lists all
data files used. ENCODE data set names are UCSC track names.
GEO data set names are GEO identifiers.
(XLS)
Table S2 Genes near brain enhancers have significant-
ly higher gene expression in brain and neural tissues
than genes near heart enhancers. Brain- or heart-related
tissues with significantly higher mean expression in genes
associated with predicted brain enhancers compared to predicted
heart enhancers.
(DOC)
Table S3 Genes near heart enhancers have significant-
ly higher gene expression in cardiac-related tissues
than genes near brain enhancers. Brain- or heart-related
tissues with significantly higher mean expression in genes
associated with predicted heart enhancers compared to predicted
brain enhancers.
(DOC)
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Table S4 The top 25 transcription factors for which
binding sites were most prevalent in brain, heart, and
limb enhancers.
(DOC)
Table S5 676 GWAS SNPs are found in predicted
enhancers. This Excel spreadsheet lists all GWAS SNPs from the
NHGRI database that fall within one of our predicted enhancers.
(XLSX)
Table S6 Candidate enhancer regions tested in zebra-
fish. We tested 10 candidate enhancer regions in a transgenic
zebrafish assay. This table lists the genomic coordinates (hg19) and
expression patterns observed for each construct at 24 and 48 hpf. A
representative fish is shown for each positive enhancer in (Figures 7
and S9). Candidate enhancers on chromosome 6 are near FOXC1,
and those on chromosome 16 are near FOXC2. N is the
number of zebrafish alive at the specified time point, and *
indicates expression patterns that are ‘‘suggestive,’’ but below
the 15% threshold we used for confirmed enhancers.
(DOC)
Data File S1 This ZIP archive contains BED files
(hg19 coordinates) with EnhancerFinder’s genome-wide
enhancer predictions, along with the MKL scores, for
general developmental enhancer activity, brain, heart,
and limb enhancers. The general prediction file also lists the
H3K27ac and H3K4me1 marks from the feature data overlapping
each predicted enhancer.
(ZIP)
Text S1 Text describing additional analyses in support
of the manuscript.
(DOC)
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